Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Immuneering Corp Cl A
(NQ:
IMRX
)
2.470
+0.100 (+4.22%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immuneering Corp Cl A
< Previous
1
2
Next >
Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
May 04, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces $30 Million Underwritten Offering
April 18, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
April 18, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
April 05, 2023
- Investor call to be held at 9:00 a.m. ET on April 18, 2023 -
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Appoints Harold E. Brakewood as Chief Business Officer
March 28, 2023
Seasoned biopharma executive with global business development, commercialization, and new product planning expertise to support the development of a universal-RAS franchise
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
March 14, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
March 06, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
March 05, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces Participation in March Investor Conferences
February 28, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
February 27, 2023
Management to host conference call on Monday, March 6 at 4:30 p.m. ET
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering To Present at Guggenheim 2023 Oncology Conference
January 31, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations
November 28, 2022
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITC
November 10, 2022
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 10, 2022
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces Participation in November Investor Conferences
November 03, 2022
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Appoints Leah R. Neufeld as Chief People Officer
October 20, 2022
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 05, 2022
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
September 30, 2022
Initiation of Phase 1/2a Clinical Trial Expected to Occur in Q4 2022
From
Immuneering Corporation
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.